Literature DB >> 24175215

History of polio vaccination.

Anda Baicus1.   

Abstract

Poliomyelitis is an acute paralytic disease caused by three poliovirus (PV) serotypes. Less than 1% of PV infections result in acute flaccid paralysis. The disease was controlled using the formalin-inactivated Salk polio vaccine (IPV) and the Sabin oral polio vaccine (OPV). Global poliomyelitis eradication was proposed in 1988 by the World Health Organization to its member states. The strategic plan established the activities required for polio eradication, certification for regions, OPV cessation phase and post-OPV phase. OPV is the vaccine of choice for the poliomyelitis eradication program because it induces both a systemic and mucosal immune response. The major risks of OPV vaccination are the appearance of Vaccine-Associated Paralytic Poliomyelitis cases (VAPP) and the emergence of Vaccine Derived Polioviruses strains. The supplementary immunization with monovalent strains of OPV type 1 or type 3 or with a new bivalent oral polio vaccine bOPV (containing type 1 and type 3 PV) has been introduced in those regions where the virus has been difficult to control. Most countries have switched the schedule of vaccination by using IPV instead of OPV because it poses no risk of vaccine-related disease. Until 2008, poliomyelitis was controlled in Romania, an Eastern European country, predominantly using OPV. The alternative vaccination schedule (IPV/OPV) was implemented starting in September 2008, while beginning in 2009, the vaccination was IPV only. The risk of VAPP will disappear worldwide with the cessation of use of OPV. The immunization for polio must be maintained for at least 5 to 10 years using IPV.

Entities:  

Keywords:  Formalin-inactivated polio vaccine; Oral polio vaccine; Poliomyelitis

Year:  2012        PMID: 24175215      PMCID: PMC3782271          DOI: 10.5501/wjv.v1.i4.108

Source DB:  PubMed          Journal:  World J Virol        ISSN: 2220-3249


  35 in total

Review 1.  Francis field trial of inactivated poliomyelitis vaccine: background and lessons for today.

Authors:  A S Monto
Journal:  Epidemiol Rev       Date:  1999       Impact factor: 6.222

2.  Poliomyelitis virus in urban sewage in epidemic and in nonepidemic times.

Authors:  J L MELNICK
Journal:  Am J Hyg       Date:  1947-03

3.  Update on vaccine-derived polioviruses.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2006-10-13       Impact factor: 17.586

4.  Progress toward interruption of wild poliovirus transmission--worldwide, 2008.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-04-03       Impact factor: 17.586

5.  My role in the discovery and classification of the enteroviruses.

Authors:  J L Melnick
Journal:  Annu Rev Microbiol       Date:  1996       Impact factor: 15.500

6.  Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania.

Authors:  M Combiescu; S Guillot; A Persu; A Baicus; D Pitigoi; J Balanant; G Oprisan; R Crainic; F Delpeyroux; A Aubert-Combiescu
Journal:  Arch Virol       Date:  2007-01-03       Impact factor: 2.574

Review 7.  Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease.

Authors:  P M Strebel; R W Sutter; S L Cochi; R J Biellik; E W Brink; O M Kew; M A Pallansch; W A Orenstein; A R Hinman
Journal:  Clin Infect Dis       Date:  1992-02       Impact factor: 9.079

8.  The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative.

Authors:  Anda Băicuş; Ana Persu; Mariana Combiescu; A Aubert-Combiescu
Journal:  Roum Arch Microbiol Immunol       Date:  2007 Jan-Jun

9.  Paralytic poliomyelitis in Romania, 1984-1992. Evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection.

Authors:  P M Strebel; A Aubert-Combiescu; N Ion-Nedelcu; S Biberi-Moroeanu; M Combiescu; R W Sutter; O M Kew; M A Pallansch; P A Patriarca; S L Cochi
Journal:  Am J Epidemiol       Date:  1994-12-15       Impact factor: 4.897

10.  Intramuscular injections within 30 days of immunization with oral poliovirus vaccine--a risk factor for vaccine-associated paralytic poliomyelitis.

Authors:  P M Strebel; N Ion-Nedelcu; A L Baughman; R W Sutter; S L Cochi
Journal:  N Engl J Med       Date:  1995-02-23       Impact factor: 91.245

View more
  22 in total

Review 1.  Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity.

Authors:  Laura Pöyhönen; Jacinta Bustamante; Jean-Laurent Casanova; Emmanuelle Jouanguy; Qian Zhang
Journal:  J Clin Immunol       Date:  2019-05-23       Impact factor: 8.317

Review 2.  Toward rational vaccine engineering.

Authors:  Yashavantha L Vishweshwaraiah; Nikolay V Dokholyan
Journal:  Adv Drug Deliv Rev       Date:  2022-02-09       Impact factor: 15.470

3.  Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines.

Authors:  Yoshikazu Honda-Okubo; Jeremy Baldwin; Nikolai Petrovsky
Journal:  Pathogens       Date:  2021-04-21

4.  Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics.

Authors:  Alaa F Nahhas; Alrayan F Nahhas; Thomas J Webster
Journal:  Nanomedicine (Lond)       Date:  2021-05-14       Impact factor: 5.307

5.  Mobilizing political support proved critical to a successful switch from tOPV to bOPV in Kano, Nigeria 2016.

Authors:  Bashir Abba; Sule Abdullahi; Samuel Bawa; Kabir Ibrahim Getso; Imam Wada Bello; Charles Korir; Audu Musa; Fiona Braka; Adamu Ningi; Peter Nsubuga; Richard Banda; Sisay G Tegegne; Faisal Shuaib; Usman Said Adamu; Sulaiman Haladu
Journal:  BMC Public Health       Date:  2018-12-13       Impact factor: 3.295

6.  Technology update: dissolvable microneedle patches for vaccine delivery.

Authors:  Aoife M Rodgers; Ana Sara Cordeiro; Ryan F Donnelly
Journal:  Med Devices (Auckl)       Date:  2019-09-19

Review 7.  Formulation technologies for oral vaccines.

Authors:  R R C New
Journal:  Clin Exp Immunol       Date:  2019-08-08       Impact factor: 4.330

8.  A multi-pronged scoping review approach to understanding the evolving implementation of the Smallpox and Polio eradication programs: what can other Global Health initiatives learn?

Authors:  Meike Schleiff; Adetoun Olateju; Ellie Decker; Abigail H Neel; Rasheedat Oke; Michael A Peters; Aditi Rao; Olakunle Alonge
Journal:  BMC Public Health       Date:  2020-12-18       Impact factor: 3.295

9.  Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.

Authors:  Fatima Mir; Farheen Quadri; Ondrej Mach; Imran Ahmed; Zaid Bhatti; Asia Khan; Najeeb Ur Rehman; Elias Durry; Maha Salama; Steven M Oberste; William C Weldon; Roland W Sutter; Anita K M Zaidi
Journal:  Lancet Infect Dis       Date:  2015-06-17       Impact factor: 25.071

Review 10.  The dichotomy of pathogens and allergens in vaccination approaches.

Authors:  Fiona J Baird; Andreas L Lopata
Journal:  Front Microbiol       Date:  2014-07-16       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.